These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25472499)

  • 21. New therapeutic options for chemotherapy-resistant metastatic breast cancer: the epothilones.
    Pronzato P
    Drugs; 2008; 68(2):139-46. PubMed ID: 18197722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer.
    Perez EA; Patel T; Moreno-Aspitia A
    Breast Cancer Res Treat; 2010 Jun; 121(2):261-71. PubMed ID: 20229176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ixabepilone and other epothilones: microtubule-targeting agents for metastatic breast cancer.
    Morris PG; Fornier MN
    Clin Adv Hematol Oncol; 2009 Feb; 7(2):115-22. PubMed ID: 19367253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer.
    De Luca A; D'Alessio A; Maiello MR; Gallo M; Chicchinelli N; Pergameno M; Piccirilli MS; Normanno N
    Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1177-85. PubMed ID: 26073581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial.
    Fountzilas G; Kotoula V; Pectasides D; Kouvatseas G; Timotheadou E; Bobos M; Mavropoulou X; Papadimitriou C; Vrettou E; Raptou G; Koutras A; Razis E; Bafaloukos D; Samantas E; Pentheroudakis G; Skarlos DV
    PLoS One; 2013; 8(7):e69256. PubMed ID: 23935969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies.
    Lechleider RJ; Kaminskas E; Jiang X; Aziz R; Bullock J; Kasliwal R; Harapanhalli R; Pope S; Sridhara R; Leighton J; Booth B; Dagher R; Justice R; Pazdur R
    Clin Cancer Res; 2008 Jul; 14(14):4378-84. PubMed ID: 18628451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ixabepilone, a new treatment option for metastatic breast cancer.
    Toppmeyer DL; Goodin S
    Am J Clin Oncol; 2010 Oct; 33(5):516-21. PubMed ID: 20023567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer.
    McMeekin S; Dizon D; Barter J; Scambia G; Manzyuk L; Lisyanskaya A; Oaknin A; Ringuette S; Mukhopadhyay P; Rosenberg J; Vergote I
    Gynecol Oncol; 2015 Jul; 138(1):18-23. PubMed ID: 25925990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer.
    Roché H; De Benedictis E; Cottura E; Govi S; Dalenc F; Locatelli A; Deslandres M; Zambetti M; Gladieff L; Messina M; Gianni L
    Clin Breast Cancer; 2012 Jun; 12(3):167-74. PubMed ID: 22607766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
    Thomas E; Tabernero J; Fornier M; Conté P; Fumoleau P; Lluch A; Vahdat LT; Bunnell CA; Burris HA; Viens P; Baselga J; Rivera E; Guarneri V; Poulart V; Klimovsky J; Lebwohl D; Martin M
    J Clin Oncol; 2007 Aug; 25(23):3399-406. PubMed ID: 17606975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
    Rivera E; Lee J; Davies A
    Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma.
    Burotto M; Edgerly M; Poruchynsky M; Velarde M; Wilkerson J; Kotz H; Bates S; Balasubramaniam S; Fojo T
    Oncologist; 2015 Jul; 20(7):725-6. PubMed ID: 26040622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical studies with epothilones for the treatment of metastatic breast cancer.
    Vahdat LT
    Semin Oncol; 2008 Apr; 35(2 Suppl 2):S22-30; quiz S40. PubMed ID: 18410796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ixabepilone, a novel epothilone analog in the treatment of breast cancer.
    Pivot X; Villanueva C; Chaigneau L; Nguyen T; Demarchi M; Maurina T; Stein U; Borg C
    Expert Opin Investig Drugs; 2008 Apr; 17(4):593-9. PubMed ID: 18363523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ixabepilone.
    Stein A
    Clin J Oncol Nurs; 2010 Feb; 14(1):65-71. PubMed ID: 20118028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer.
    Baselga J; Zambetti M; Llombart-Cussac A; Manikhas G; Kubista E; Steger GG; Makhson A; Tjulandin S; Ludwig H; Verrill M; Ciruelos E; Egyhazi S; Xu LA; Zerba KE; Lee H; Clark E; Galbraith S
    J Clin Oncol; 2009 Feb; 27(4):526-34. PubMed ID: 19075286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer.
    Corey-Lisle PK; Peck R; Mukhopadhyay P; Orsini L; Safikhani S; Bell JA; Hortobagyi G; Roche H; Conte P; Revicki DA
    Cancer; 2012 Jan; 118(2):461-8. PubMed ID: 21598243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents.
    Yardley DA
    Clin Breast Cancer; 2010 Feb; 10(1):64-73. PubMed ID: 20133261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone.
    Lee JJ; Low JA; Croarkin E; Parks R; Berman AW; Mannan N; Steinberg SM; Swain SM
    J Clin Oncol; 2006 May; 24(13):2084-91. PubMed ID: 16648510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.